1
|
Tanaka S, Noda T, Urashima K, Ijiri Y, Kohda Y, Kato R. Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin-induced liver injury. J Appl Toxicol 2024. [PMID: 38291012 DOI: 10.1002/jat.4585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 01/10/2024] [Accepted: 01/11/2024] [Indexed: 02/01/2024]
Abstract
Trovafloxacin is a quinolone antibiotic drug with broad-spectrum activity, which was withdrawn from a global market relatively soon after approval because of serious liver injury. The characteristics of trovafloxacin-induced liver injury are consistent with an idiosyncratic reaction; however, the details of the mechanism have not been elucidated. We examined whether trovafloxacin induces the release of damage-associated molecular patterns (DAMPs) that activate inflammasomes. We also tested ciprofloxacin, levofloxacin, gatifloxacin, and grepafloxacin for their ability to activate inflammasomes. Drug bioactivation was performed with human hepatocarcinoma functional liver cell-4 (FLC-4) cells, and THP-1 cells (human monocyte cell line) were used for the detection of inflammasome activation. The supernatant from the incubation of trovafloxacin with FLC-4 cells for 7 days increased caspase-1 activity and production of IL-1ß by THP-1 cells. In the supernatant of FLC-4 cells that had been incubated with trovafloxacin, heat shock protein (HSP) 40 was significantly increased. Addition of a cytochrome P450 inhibitor to the FLC-4 cells prevented the release of HSP40 from the FLC-4 cells and inflammasome activation in THP-1 cells by the FLC-4 supernatant. These results suggest that reactive metabolites of trovafloxacin can cause the release of DAMPs from hepatocytes that can activate inflammasomes. Inflammasome activation may be an important step in the activation of the immune system by trovafloxacin, which, in some patients, can cause immune-related liver injury.
Collapse
Affiliation(s)
- Saori Tanaka
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Takumi Noda
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Kazuya Urashima
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Yoshio Ijiri
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Yuka Kohda
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Ryuji Kato
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| |
Collapse
|
2
|
Kato R, Yamada T, Noda T, Tanaka S, Kohda Y, Ijiri Y. Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes. Toxicol In Vitro 2023; 90:105606. [PMID: 37146920 DOI: 10.1016/j.tiv.2023.105606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 04/10/2023] [Accepted: 04/27/2023] [Indexed: 05/07/2023]
Abstract
Flutamide is a non-steroidal anti-androgen agent, which is mainly used for the treatment of prostate cancer. Flutamide is known to cause severe adverse events, which includes idiosyncratic liver injury. However, details of the mechanism of these adverse reactions have not been elucidated. We investigated whether flutamide induces the release of damage-associated molecular patterns (DAMPs) that activate inflammasomes. We also tested bicalutamide, enzalutamide, apalutamide, and darolutamide for their ability to activate inflammasomes in differentiated THP-1 cells. The supernatant from the incubation of flutamide and bicalutamide with human hepatocarcinoma functional liver cell-4 (FLC-4) cells increased caspase-1 activity and production of IL-1ß by differentiated THP-1 cells. In the supernatant of FLC-4 cells with flutamide and bicalutamide, the heat shock protein (HSP) 40 or 60 was significantly increased. Addition of a carboxylesterase or a CYP inhibitor to the FLC-4 cells prevented release of HSPs from the FLC-4 cells. These results suggested that the reactive metabolites of flutamide and bicalutamide can cause the release of DAMPs from hepatocytes and activate inflammasomes. Inflammasome activation may be an important step in the activation of the immune system by flutamide or bicalutamide, which in some patients, can cause immune-related adverse events.
Collapse
Affiliation(s)
- Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan.
| | - Tomoyuki Yamada
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Osaka 569-8686, Japan
| | - Takumi Noda
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Saori Tanaka
- Department of Pharmacotherapeutics, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Yuka Kohda
- Department of Pharmacotherapeutics, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| |
Collapse
|
3
|
Yamada T, Kato R, Ijiri Y, Nishihara M, Neo M. Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors. Int J Clin Pharm 2023; 45:442-450. [PMID: 36609809 DOI: 10.1007/s11096-022-01527-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 11/30/2022] [Indexed: 01/07/2023]
Abstract
BACKGROUND Although acetaminophen is recommended for the treatment of mild-to-moderate cancer pain, acetaminophen-induced hepatic disorders pose an important clinical challenge. Concomitant prescription of immune checkpoint inhibitors (ICIs) may further increase the risk of hepatic disorders in patients taking acetaminophen; however, there are few clinical studies that confirm this. AIM To evaluate the risk of hepatic disorders in patients taking concomitant acetaminophen and ICIs using a disproportionality analysis from the Japanese Adverse Drug Event Report database. METHOD Acetaminophen users aged ≥ 20 years were included; factors that can affect the risk of acetaminophen-induced hepatic disorders were collated. Similar data on the widely used analgesic, loxoprofen, were used for comparison. RESULTS Among 233,594 patients surveyed, 10,403 were prescribed acetaminophen, and among them, 1,245 patients developed hepatic disorders. The disproportionality of hepatic disorders was observed in acetaminophen users regardless of concomitant ICI use (without ICI: reporting odds ratio [ROR], 1.18; 95% confidence intervals [CI], 1.10-1.26; with ICI: ROR 1.87, 95%CI 1.59-2.20); it was even higher in concomitant acetaminophen and ICI users (ROR 1.94, 95%CI 1.65-2.29). However, increased disproportionality of hepatic disorders was not observed in patients taking concomitant loxoprofen and ICI. Multivariable logistic regression showed that the risk of hepatic disorders in acetaminophen users was associated with concomitant use of ICI (ROR, 1.91; 95% CI, 1.49-2.45); (P < 0.01). CONCLUSION Our findings suggest that the risk of hepatic disorders is greater with concomitant acetaminophen and ICI treatment than with acetaminophen alone.
Collapse
Affiliation(s)
- Tomoyuki Yamada
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
| | - Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Masami Nishihara
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan
| | - Masashi Neo
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan
| |
Collapse
|
4
|
Noda T, Kato R, Ozato Y, Kawai Y, Yamamoto M, Kagawa Y, Azuma M, Yamamoto K, Kusanagi M, Uryu K, Harada H, Ijiri Y, Hayashi T, Tanaka K. Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen-induced liver injury. Biopharm Drug Dispos 2022; 43:108-116. [PMID: 35508086 DOI: 10.1002/bdd.2316] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 04/08/2022] [Accepted: 04/15/2022] [Indexed: 02/05/2023]
Abstract
Acetaminophen (APAP)-induced liver injury (AILI) is the most common cause of acute liver failure. Although the mechanisms that trigger AILI are well known, it is less understood how to halt AILI progression and facilitate liver recovery. Therefore, it is necessary to understand the pathophysiology of APAP hepatotoxicity in patients and to examine predictive/preventive markers. In a clinical study, we had a case in which aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels increased in a patient with a low ratio of APAP glucuronide concentration (AP-G)/APAP plasma concentration. Then a reverse translational study was conducted for clarifying this clinical question. The relationship between plasma AP-G/APAP concentration ratio and the levels of AST and ALT was examined by in vivo and in vitro experiments. In in vivo experiments, 10-week-old rats showed lower UGT activity, lower AP-G/APAP concentration ratios, and higher AST and ALT levels than 5-week-old rats. This suggests an inverse correlation between the AP-G/APAP concentration ratio and the AST, ALT levels in APAP-treated rats. Furthermore, as a result of the in vitro experiment, it was confirmed that the cell viability decreased when the AP-G/APAP concentration ratio in the culture medium decreased. Since the decrease in the plasma AP-G/APAP concentration ratio appears earlier than the increase of AST and ALT levels, the ratio might be a presymptomatic marker of AILI. When APAP is used for a long time, it is recommended to perform therapeutic drug monitoring of the AP-G/APAP concentration ratio, which is a predictive/preventive marker of AILI.
Collapse
Affiliation(s)
- Takumi Noda
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Yasuyuki Ozato
- Yao Tokusyukai General Hospital, 1-17 wakakusacho, Yao, Osaka, 581-0011, Japan
| | - Yuka Kawai
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Masato Yamamoto
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Yuya Kagawa
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Misa Azuma
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Kojiro Yamamoto
- Yao Tokusyukai General Hospital, 1-17 wakakusacho, Yao, Osaka, 581-0011, Japan
| | - Mika Kusanagi
- Yao Tokusyukai General Hospital, 1-17 wakakusacho, Yao, Osaka, 581-0011, Japan
| | - Kiyoaki Uryu
- Yao Tokusyukai General Hospital, 1-17 wakakusacho, Yao, Osaka, 581-0011, Japan
| | - Hiromasa Harada
- Yao Tokusyukai General Hospital, 1-17 wakakusacho, Yao, Osaka, 581-0011, Japan
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan
| | - Kazuhiko Tanaka
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.,Kidney Center, Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyoshi-ku, Osaka, 546-0002, Japan
| |
Collapse
|
5
|
Kato R, Ijiri Y. Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events. Pharmazie 2022; 77:54-58. [PMID: 35209964 DOI: 10.1691/ph.2022.1955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Multi-targeted tyrosine kinase inhibitors have been developed for the treatment of various cancers, but they are associated with a significant incidence of idiosyncratic drug reactions (IDRs). There is compelling evidence that most IDRs are immune mediated. Activation of inflammasomes is often one of the early steps in the initiation of an immune response. This activation could involve the pharmacological effect of the drug, or it could involve the release of damage associated molecular patters (DAMPs) caused by a reactive metabolite. We tested whether sunitinib, regorafenib, lenvatinib and cabozantinib can directly activate inflammasomes in differentiated THP-1 cells. We found that regorafenib activated the inflammasome of differentiated THP-1 cells directly. We also found that the supernatant from the incubation of sunitinib with FLC-4 cells, which have a high capacity to metabolize drugs, led to activate the inflammasome of differentiated THP-1 cells. In the supernatant of FLC-4 cells with sunitinib, the heat shock protein (HSP) 90 was significantly increased. Sunitinib is known to be oxidized to generate a reactive, potentially toxic quinone imine. These results support the hypothesis that the reactive metabolite of sunitinib can cause the release of DAMPs from hepatocytes, which leads to activation of inflammasomes. Inflammasome activation may be an important step in the activation of the immune system by regorafenib and sunitinib, which in some patients, can cause IDRs.
Collapse
Affiliation(s)
- R Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan;,
| | - Y Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan
| |
Collapse
|
6
|
Noda T, Kato R, Hattori T, Furukawa Y, Ijiri Y, Tanaka K. Role of caspase-8 and/or -9 as biomarkers that can distinguish the potential to cause toxic- and immune related-adverse event, for the progress of acetaminophen-induced liver injury. Life Sci 2022; 294:120351. [PMID: 35092733 DOI: 10.1016/j.lfs.2022.120351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 01/17/2022] [Accepted: 01/18/2022] [Indexed: 10/19/2022]
Abstract
AIMS Acetaminophen (APAP) overdose can cause acute liver failure. Although it is well known that APAP-induced liver injury (AILI) is caused by toxic mechanism, recently it is also reported to be immune related. However, the detail of the mechanism has been unclear. Therefore, elucidation of the pathophysiology is required. MAIN METHODS In AILI model rats (800 mg/kg), the levels of AST, ALT and Caspase (C)-3/-8/-9 levels were measured. In in vitro study using human hepatocyte cells (FLC-4) and THP-1 cells, APAP (1.0 mM) were added to FLC-4 and the cell viability, C-9, cytochrome c, mitochondria membrane potential, and glutathione levels of FLC-4 and inflammasome activation of THP-1 were evaluated. KEY FINDINGS In AILI model rats, the levels of AST and ALT were increased only at 12-24 h. C-3/-9 levels rose at 6-9 h, whereas C-8 level rose hours later, moreover, 24 h after; C-3/-8/-9 levels re-rose. In FLC-4 cells, cytochrome c was released from the mitochondria which is promoted by oxidative stress due to drug metabolism and C-9 was activated. Thus, AILI was caused mitochondrial damage by NAPQI as early reaction (first stage). In the next stage, inflammasomes of human antigen presenting cells, which released inflammatory cytokines were activated by damage-associated molecular patterns (DAMPs) released from damaged hepatocyte by APAP. SIGNIFICANCE It is confirmed that AILI includes immune related mechanism. Thereby, in case of N-acetylcysteine refractory, additional administration of steroid hormones should be effective and recommended as a novel strategy for AILI with immune related adverse event (irAE).
Collapse
Affiliation(s)
- Takumi Noda
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan
| | - Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan
| | - Tomoko Hattori
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan
| | - Yuichi Furukawa
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan.
| | - Kazuhiko Tanaka
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka Medical and Pharmaceutical University, Nasahara, Takatsuki, Osaka, Japan; Kidney Center, Shirasagi Hospital, Kumata, Higashisumiyoshi-ku, Osaka, Japan
| |
Collapse
|
7
|
Kato R, Ijiri Y, Hayashi T. Amiodarone, Unlike Dronedarone, Activates Inflammasomes via Its Reactive Metabolites: Implications for Amiodarone Adverse Reactions. Chem Res Toxicol 2021; 34:1860-1865. [PMID: 34142814 DOI: 10.1021/acs.chemrestox.1c00127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Amiodarone is a benzofuran derivative used to treat arrhythmias, but its use is limited by adverse reactions. There is evidence that some of the severe adverse reactions such as liver injury and interstitial lung disease are immune-mediated; however, details of the mechanism have not been elucidated. We tested the ability of amiodarone to induce the release of danger-associated molecular patterns (DAMPs) that activate inflammasomes. Human hepatocarcinoma functional liver cell-4 (FLC-4) cells were used for drug bioactivation, and the detection of inflammasome activation was performed with the human macrophage cell line, THP-1 cells. Amiodarone is known to be oxidized to reactive quinone metabolites. The supernatant from the incubation of amiodarone with FLC-4 cells for 7 days increased caspase-1 activity and production of IL-1ß by THP-1 cells. In the supernatant of FLC-4 cells with amiodarone, the heat shock protein (HSP) 40 was significantly increased. Addition of a cytochrome P450 inhibitor to the FLC-4 cells prevented the release of HSP40 from the FLC-4 cells and activation of THP-1 inflammasomes by the FLC-4 supernatant. These results suggested that the reactive quinone metabolites of amiodarone can cause the release of DAMPs from hepatocytes which can activate inflammasomes. Dronedarone, a safer analog of amiodarone, did not activate inflammasomes. Inflammasome activation may be an important step in the activation of the immune system by amiodarone, which in some patients, can cause immune-related adverse events. In addition, our data suggest that drugs that block the effects or the formation of IL-1β would provide better treatment of amiodarone-induced immune-related adverse reactions.
Collapse
Affiliation(s)
- Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan
| |
Collapse
|
8
|
Imano H, Kato R, Nomura A, Tamura M, Yamaguchi Y, Ijiri Y, Wu H, Nakano T, Okada Y, Yamaguchi T, Izumi Y, Yoshiyama M, Asahi M, Hayashi T. Rivaroxaban Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Hypertension. Biol Pharm Bull 2021; 44:669-677. [PMID: 33612567 DOI: 10.1248/bpb.b20-01011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a progressive condition that frequently results in right ventricular (RV) remodeling. The objectives of this study are to investigate effects of rivaroxaban on RV remodeling in a rat model of PAH, created with Sugen5416 and chronic hypoxia, and the in vitro effects of rivaroxaban on human cardiac microvascular endothelial cells (HCMECs). To create the PAH model, male Sprague-Dawley rats were subcutaneously injected with Sugen5416 (20 mg/kg) and exposed to 2 weeks of hypoxia (10% O2), followed by 2 weeks of exposure to normoxia. The animals were then divided into 2 groups with or without administration of rivaroxaban (12 mg/kg/d) for a further 4 weeks. HCMECs were cultured under hypoxic conditions (37 °C, 1% O2, 5% CO2) with Sugen5416 and with or without rivaroxaban. In the model rats, RV systolic pressure and Fulton index increased by hypoxia with Sugen5416 were significantly decreased when treated with rivaroxaban. In HCMECs, hypoxia with Sugen5416 increased the expression of protease-activated receptor-2 (PAR-2) and the phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and nuclear factor-kappa B (NF-κB), while treatment with rivaroxaban significantly suppressed the expression of these proteins. Rivaroxaban attenuated RV remodeling in a rat model of PAH by reducing ERK, JNK and NF-κB activation. Rivaroxaban has the possibility of providing additive effects on RV remodeling in patients with PAH.
Collapse
Affiliation(s)
- Hideki Imano
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Atsuo Nomura
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
- Department of Pharmacology, Faculty of Medicine, Osaka Medical College
| | - Maki Tamura
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yudai Yamaguchi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Hong Wu
- Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical College
| | - Takashi Nakano
- Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical College
| | - Yoshikatsu Okada
- Department of Pathology, Faculty of Medicine, Osaka Medical College
| | - Takehiro Yamaguchi
- Department of Pharmacology, Osaka City University Graduate School of Medicine
| | - Yasukatsu Izumi
- Department of Pharmacology, Osaka City University Graduate School of Medicine
| | - Minoru Yoshiyama
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine
| | - Michio Asahi
- Department of Pharmacology, Faculty of Medicine, Osaka Medical College
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
9
|
Imano H, Kato R, Ijiri Y, Hayashi T. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro 2020; 71:105063. [PMID: 33271325 DOI: 10.1016/j.tiv.2020.105063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 11/17/2020] [Accepted: 11/28/2020] [Indexed: 11/25/2022]
Abstract
Vascular endothelial growth factor (VEGF) promotes tumor angiogenesis through stimulating the proliferation and survival of endothelial cells. The severe adverse events caused by VEGF inhibitors might include immune-related ones; however, details of the mechanism have not been elucidated. We tested whether axitinib, pazopanib, sorafenib, and sunitinib, which are tyrosine kinase inhibitors (TKIs) of VEGF receptor used for the therapy of renal cell carcinoma can activate inflammasomes in differentiated THP-1 cells, a human macrophage cell line. We also performed similar studies with semaxanib. In this study, semaxanib and sorafenib activated the inflammasome of differentiated THP-1 cells. Although pazopanib increased the production of IL-1β, inflammasomes were not activated because caspase-1 was not activated in differentiated THP-1 cells. Our results support the hypothesis that activation of inflammasomes contributes to the idiosyncratic reactions associated with semaxanib and sorafenib. Although pazopanib did not activate inflammasomes, it did cause increased IL-1β production, which may facilitate the induction of idiosyncratic reactions.
Collapse
Affiliation(s)
- Hideki Imano
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan
| | - Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan.
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan
| |
Collapse
|
10
|
Kato R, Ijiri Y, Hayashi T, Uetrecht J. Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci 2020; 45:673-680. [DOI: 10.2131/jts.45.673] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshio Ijiri
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Jack Uetrecht
- Department of Pharmaceutical Scinces, Faculty of Pharmacy, University of Toronto, Canada
| |
Collapse
|
11
|
Kato R, Sato T, Iwamoto A, Yamazaki T, Nakashiro S, Yoshikai S, Fujimoto A, Imano H, Ijiri Y, Mino Y, Chikuma M, Tanaka K, Hayashi T. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albuminin vivorats andin vitrostudy using inductively coupled plasma-mass spectrometory. Biopharm Drug Dispos 2019; 40:242-249. [DOI: 10.1002/bdd.2197] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 04/12/2019] [Accepted: 06/02/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Takaji Sato
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
- Education and Research Center for Fundamental Pharmaceutical Sciences; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Asuka Iwamoto
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Taku Yamazaki
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Satomi Nakashiro
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Shoichi Yoshikai
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Ayumi Fujimoto
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Hideki Imano
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | | | - Yoshiki Mino
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
| | - Masahiko Chikuma
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
| | - Kazuhiko Tanaka
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
- Shirasagi Hospital; 7-11-23 Kumata Higashisumiyosi-ku, Osaka 546-0002 Japan
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| |
Collapse
|
12
|
Kato R, Ijiri Y, Hayashi T, Uetrecht J. The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions. Drug Metab Dispos 2019; 47:1093-1096. [DOI: 10.1124/dmd.119.087981] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 07/10/2019] [Indexed: 12/29/2022] Open
|
13
|
Hayashi T, Matsumoto S, Hosokawa A, Yamamoto K, Nomura A, Woo E, Imano H, Kato R, Ijiri Y, Yamaguchi T, Izumi Y, Yoshiyama M, Okada Y, Asahi M. P2501Rivaroxaban combined with spironolactone attenuates cardiovascular remodeling due to hypoxia in pulmonary arterial hypertension. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- T Hayashi
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - S Matsumoto
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - A Hosokawa
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - K Yamamoto
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - A Nomura
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - E Woo
- Osaka Medical College, Takatsuki, Japan
| | - H Imano
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - R Kato
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Y Ijiri
- Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | | | - Y Izumi
- Osaka City University, Osaka, Japan
| | | | - Y Okada
- Osaka Medical College, Takatsuki, Japan
| | - M Asahi
- Osaka Medical College, Takatsuki, Japan
| |
Collapse
|
14
|
Woo E, Kato R, Imano H, Fujiwara Y, Ijiri Y, Okada Y, Yamaguchi T, Izumi Y, Yoshiyama M, Katsumata T, Hayashi T. Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416. Curr Vasc Pharmacol 2018; 15:589-598. [PMID: 28460626 DOI: 10.2174/1570161115666170427154217] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2016] [Revised: 04/13/2017] [Accepted: 04/13/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Sugen5416 (semaxinib) is an inhibitor of the vascular endothelial growth factor (VEGF) receptor. A rat model of Pulmonary Arterial Hypertension (PAH), created with Sugen5416 and chronic hypoxia, is known to have similar histological findings to those of PAH patients. OBJECTIVE To evaluate the pathophysiological mechanisms of cardiac remodeling due to hypoxic stress with Sugen5416 in vivo. METHODS Male Sprague-Dawley rats were exposed to hypoxia (10 ± 1% O2) for 2 weeks after a single injection of Sugen5416 (SU-hypoxia group) or the vehicle (V-hypoxia group). RESULTS Hypoxia elevated right ventricular (RV) systolic pressure and caused RV remodeling on Day 14. By electron microscopy, metamorphosis of capillaries with endothelial cell occlusive degeneration was observed in the RV myocardium of the SU-hypoxia group from Day 3. After reoxygenation, progressive RV remodeling with extensive degeneration of cardiomyocytes was observed in the SUhypoxia group, associated with a significant increase of oxidative stress and TUNEL-positive cells in both RV and left ventricular myocardium on Day 84. The expression of VEGF mRNA in the RV myocardium was significantly suppressed in the SU-hypoxia group on Day 3, whereas delayed activation of VEGF/extracellular signal-regulated kinase (ERK) signaling pathway on Day 14 were observed. CONCLUSION Capillary degeneration and activation of VEGF/ERK signaling pathway might be crucial to accelerate the cardiac remodeling due to hypoxic stress with Sugen5416.
Collapse
Affiliation(s)
- Eiki Woo
- Department of Thoracic and Cardiovascular Surgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686. Japan
| | - Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094. Japan
| | - Hideki Imano
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094. Japan
| | - Yuji Fujiwara
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094. Japan
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094. Japan
| | - Yoshikatsu Okada
- Department of Pathology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686. Japan
| | - Takehiro Yamaguchi
- Department of Cardiovascular Medicine, Osaka City University, Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585. Japan
| | - Yasukatsu Izumi
- Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585. Japan
| | - Minoru Yoshiyama
- Department of Cardiovascular Medicine, Osaka City University, Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585. Japan
| | - Takahiro Katsumata
- Department of Thoracic and Cardiovascular Surgery, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686. Japan
| | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094. Japan
| |
Collapse
|
15
|
Hannya N, Ogita-Nakanishi H, Kato R, Ijiri Y, Hayashi T, Tanaka K, Kawata R, Takenaka H, Kubota T, Yoshida R. The 1st step initiation essential for allergen-specific IgE antibody production upon the 2nd step: Induction of non-specific IgE + small B cells containing secondly-sensitized allergen-specific ones in mice firstly-sensitized with an allergen. Microbiol Immunol 2017; 62:99-110. [PMID: 29193290 DOI: 10.1111/1348-0421.12558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 11/01/2017] [Accepted: 11/24/2017] [Indexed: 11/28/2022]
Abstract
There was a significant amount of non-specific, but not of allergen (e.g., papain, mite feces and four kinds of pollen)-specific, IgE antibodies (Abs) in the sera of normal mice. An i.n. injection of each allergen without adjuvant into mice caused an increase in total IgE Ab titers with a similar time course in the serum. However, the stage of initiation of allergy varied from allergen to allergen. Submandibular lymph node cells from normal mice contained papain-, but not mite feces- or pollen-specific IgE+ cells and an i.n. injection of papain induced papain-specific IgE Abs in the serum. In contrast, one (i.n.) or two (i.n. and s.c) injections of mite feces induced neither mite feces-specific IgE+ cells in the lymph nodes nor mite feces-specific IgE Abs in the serum. I.n. sensitization with cedar pollen induced cedar pollen-specific IgE+ small B cells in the lymph nodes on Day 10, when non-specific IgE Ab titers reached a peak in the serum, implying induction of related allergen-specific IgE+ small cells as well. In fact, a second (s.c.) injection of ragweed (or cedar) pollen into mice sensitized i.n. once with cedar (or ragweed) pollen, but not with mite feces, induced a large amount of ragweed (or cedar) pollen-specific IgE Abs in the serum. These results indicate that when firstly-sensitized non-specific IgE+ small B cells in mouse lymph nodes include some secondly-sensitized allergen-specific ones, mice produce IgE Abs specific for the secondly-injected allergen.
Collapse
Affiliation(s)
- Natsuki Hannya
- Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan.,Department of Clinical Pharmacy, and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094, Japan
| | - Hiromi Ogita-Nakanishi
- Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan.,Department of Otorhinolaryngology, Osaka Medical College, Takatsuki 569-8686, Japan
| | - Ryuji Kato
- Department of Clinical Pharmacy, and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094, Japan
| | - Yoshio Ijiri
- Department of Clinical Pharmacy, and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094, Japan
| | - Tetsuya Hayashi
- Department of Clinical Pharmacy, and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094, Japan
| | - Kazuhiko Tanaka
- Department of Clinical Pharmacy, and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki 569-1094, Japan
| | - Ryo Kawata
- Department of Otorhinolaryngology, Osaka Medical College, Takatsuki 569-8686, Japan
| | - Hiroshi Takenaka
- Department of Otorhinolaryngology, Osaka Medical College, Takatsuki 569-8686, Japan
| | - Takahiro Kubota
- Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan
| | - Ryotaro Yoshida
- Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan
| |
Collapse
|
16
|
Shimada M, Imano H, Fujiwara A, Hashimoto T, Kato R, Ijiri Y, Izumi Y, Yoshiyama M, Hayashi T. P5147Direct factor Xa inhibition prevents cardiac remodeling induced by intermittent hypoxia through PAR-1/2 dual signaling pathway. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Mizuuchi T, Sano F, Nagasaki K, Okada H, Kobayashi S, Hanatani K, Torii Y, Ijiri Y, Senju T, Yaguchi K, Sakamoto K, Toshi K, Shibano M, Kondo K, Nakamura Y, Kaneko M, Arimoto H, Motojima G, Fujikawa S, Kitagawa H, Nakamura H, Tsuji T, Uno M, Watanabe S, Yabutani H, Matsuoka S, Nosaku M, Watanabe N, Yamamoto S, Watanabe KY, Suzuki Y, Yokoyama M. Configuration Control for the Confinement Improvement in Heliotron J. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1256] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Mizuuchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - F. Sano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Nagasaki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - H. Okada
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - S. Kobayashi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Hanatani
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - Y. Torii
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - Y. Ijiri
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - T. Senju
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Yaguchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Sakamoto
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Toshi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - M. Shibano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Kondo
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Y. Nakamura
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - M. Kaneko
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Arimoto
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - G. Motojima
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Fujikawa
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Kitagawa
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Nakamura
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - T. Tsuji
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - M. Uno
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Watanabe
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Yabutani
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Matsuoka
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - M. Nosaku
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - N. Watanabe
- Kyoto University, Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Yamamoto
- Osaka University, Graduate School of Engineering, Yamadaoka 1-1 Suita 565-0871, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science Oroshi-cho 322-6, Toki 509-5292, Japan
| | - Y. Suzuki
- National Institute for Fusion Science Oroshi-cho 322-6, Toki 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science Oroshi-cho 322-6, Toki 509-5292, Japan
| |
Collapse
|
18
|
Sano F, Mizuuchi T, Nagasaki K, Okada H, Kobayashi S, Kondo K, Hanatani K, Nakamura Y, Nakasuga M, Besshou S, Yamamoto S, Yokoyama M, Suzuki Y, Manabe Y, Shidara H, Takamiya T, Ohno Y, Nishioka Y, Yukimoto H, Takahashi K, Fukagawa Y, Kawazome H, Kaneko M, Tsuboi S, Nakazawa S, Nishio S, Yamada M, Ijiri Y, Senju T, Yaguchi K, Sakamoto K, Tohshi K, Shibano M, Tribaldos V, Tabares F, Obiki T. Observation of H-Mode Operation Windows for ECH Plasmas in Heliotron J. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a567] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Sano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - T. Mizuuchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Nagasaki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - H. Okada
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Kobayashi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Kondo
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - K. Hanatani
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - Y. Nakamura
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - M. Nakasuga
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Besshou
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Yamamoto
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Gifu, Toki, Japan
| | - Y. Suzuki
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Manabe
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Shidara
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - T. Takamiya
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Ohno
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Nishioka
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Yukimoto
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - K. Takahashi
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Fukagawa
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Kawazome
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Kaneko
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Tsuboi
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Nakazawa
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Nishio
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Yamada
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Ijiri
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - T. Senju
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Yaguchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Sakamoto
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Tohshi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - M. Shibano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - V. Tribaldos
- Laboratorio Nacional de Fusion, Asociacion EURATOMCIEMAT, Madrid, Spain
| | - F. Tabares
- Laboratorio Nacional de Fusion, Asociacion EURATOMCIEMAT, Madrid, Spain
| | - T. Obiki
- Kyushu Institute of Information Sciences, Dazaifu, Fukuoka, Japan
| |
Collapse
|
19
|
Mitsuishi R, Imano H, Kato R, Ijiri Y, Yamaguchi T, Yoshiyama M, Hayashi T. RIVAROXABAN ATTENUATES CARDIAC REMODELING DUE TO INTERMITTENT HYPOXIA BY SUPPRESSING THE SYNERGISTIC EFFECTS OF PAR-1 AND PAR-2. J Am Coll Cardiol 2017. [DOI: 10.1016/s0735-1097(17)35422-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Ijiri Y, Kato R, Sadamatsu M, Takano M, Yasuda Y, Tanaka F, Oishi C, Imano H, Okada Y, Tanaka K, Hayashi T. Contributions of caspase-8 and -9 to liver injury from CYP2E1-produced metabolites of halogenated hydrocarbons. Xenobiotica 2017; 48:60-72. [DOI: 10.1080/00498254.2016.1275881] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Yoshio Ijiri
- Cardiovascular Pharmacotherapy and Toxicology and
| | - Ryuji Kato
- Cardiovascular Pharmacotherapy and Toxicology and
| | | | - Mina Takano
- Pharmacotherapy II, Osaka University of Pharmaceutical Sciences, Nasahara, Takatsuki, Osaka, Japan,
| | - Yuki Yasuda
- Cardiovascular Pharmacotherapy and Toxicology and
| | | | - Chiyo Oishi
- Cardiovascular Pharmacotherapy and Toxicology and
| | - Hideki Imano
- Cardiovascular Pharmacotherapy and Toxicology and
| | - Yoshikatsu Okada
- Department of Pathology, Osaka Medical College, Daigaku-machi, Takatsuki, Osaka, Japan, and
| | - Kazuhiko Tanaka
- Kidney Center, Shirasagi Hospital, Kumata, Higashisumiyoshi-ku, Osaka, Japan
| | | |
Collapse
|
21
|
Kato R, Sato T, Kanamori M, Miyake M, Fujimoto A, Ogawa K, Kobata D, Fujikawa T, Wada Y, Mitsuishi R, Takahashi K, Imano H, Ijiri Y, Mino Y, Chikuma M, Tanaka K, Hayashi T. A Novel Analytical Method of Cisplatin Using the HPLC with a Naphthylethyl Group Bonded with Silica Gel (πNAP) Column. Biol Pharm Bull 2017; 40:290-296. [DOI: 10.1248/bpb.b16-00760] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Takaji Sato
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | - Michiko Kanamori
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Mizuho Miyake
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Ayumi Fujimoto
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Kyohei Ogawa
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Daiki Kobata
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Tomoya Fujikawa
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yukari Wada
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Rintaro Mitsuishi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Kodai Takahashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Hideki Imano
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshiki Mino
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | - Masahiko Chikuma
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | | | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
22
|
Kondo T, Fujiwara A, Shimada K, Fujii K, Imano H, Kato R, Ijiri Y, Yamaguchi T, Yoshiyama M, Hayashi T. Rivaroxaban Attenuates Diastolic Dysfunction and Cardiovascular Remodeling Induced by Intermittent Hypoxia in Mice. J Card Fail 2016. [DOI: 10.1016/j.cardfail.2016.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Yamada T, Kato R, Oda K, Tanaka H, Suzuki K, Ijiri Y, Ikemoto T, Nishihara M, Hayashi T, Tanaka K, Tamai H, Ukimura A, Katsumata T. False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin. Basic Clin Pharmacol Toxicol 2016; 119:353-9. [PMID: 27060578 DOI: 10.1111/bcpt.12597] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 04/01/2016] [Indexed: 12/13/2022]
Abstract
Prothrombin time (PT) can reportedly be falsely prolonged by the antimicrobial drug daptomycin (DAP), and concomitant use of phosphatidylglycerol (PG). Although high doses of DAP (>6 mg/kg/day) are recommended for severe infection and result in a high blood concentration, the extent to which high blood concentrations of DAP interfere with PT, in the presence or absence of PG, has yet to be determined when using the HemosIL RecombiPlasTin 2G (Werfen Japan, Tokyo, Japan). We examined the effects of high doses of DAP on PT using this reagent. DAP (0-500 mg/L) was added to normal plasma and plasma with an already prolonged PT in the presence or absence of liposomal amphotericin B (L-AMB, 5-50 mg/L) or COATSOME EL-01 empty cationic liposomes (CS, 25-250 mg/L). Furthermore, we undertook a Monte Carlo simulation to calculate the probability of achieving DAP concentrations >100, >200 and >500 mg/L 0-48 hr after administering 6-12 mg/kg of DAP. Apparent PT increased with increasing DAP concentration, but neither L-AMB nor CS appeared to further elevate PT when co-administered with DAP. The probability of achieving DAP concentrations >100 and >200 mg/L increased with DAP dose. Higher doses of DAP than the approved dose caused false prolongation of PT. PT should be monitored carefully in patients taking high doses of DAP; ideally, PT should be measured at the trough blood concentration of DAP. Concomitant use of L-AMB and CS did not generally further elevate PT when co-administered with DAP.
Collapse
Affiliation(s)
- Tomoyuki Yamada
- Department of Pharmacy, Osaka Medical College Hospital, Takatsuki, Osaka, Japan. .,Infection Control Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan.
| | - Ryuji Kato
- Laboratory of Cardiovascular Pharmacology and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan
| | - Kazutaka Oda
- Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan
| | - Hidema Tanaka
- Department of Clinical Laboratory, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| | - Kaoru Suzuki
- Department of Pharmacy, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacology and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan
| | - Toshiyuki Ikemoto
- Department of Clinical Laboratory, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| | - Masami Nishihara
- Department of Pharmacy, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacology and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.,Department of Internal Medicine III, Osaka Medical College, Osaka, Japan
| | | | - Hiroshi Tamai
- Department of Pediatrics, Osaka Medical College, Osaka, Japan
| | - Akira Ukimura
- Infection Control Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| | - Takahiro Katsumata
- Department of Pharmacy, Osaka Medical College Hospital, Takatsuki, Osaka, Japan
| |
Collapse
|
24
|
Kato R, Matsura A, Kamiya R, Oishi C, Kagawa Y, Tanaka F, Matsumoto N, Ijiri Y, Hayashi T. Effect of hypoxia on UDP-glucuronosyl transferase mRNA expression in human hepatocarcinoma functional liver celL4 cell line. Pharmazie 2016; 71:152-153. [PMID: 27183710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Although hypoxic conditions have been reported to affect the expression levels of various enzymes like cytochrome P450, the effect of hypoxia for UDP-glucuronosyl transferase (UGT) expression has been unclear. We evaluated the mRNA expression of UGTs (UGT1A1·1A6·1A9·2B7) in a functional liver cell-4 (FLC-4) cell line by three-dimensional culture under hypoxic conditions (37 °C, 1% O₂, 5% CO₂) fo 7 days. The mRNA expression of UGT1A1·1A6·1A9·2B7 decreased significantly after 3 days and that of UGT1A1·1A6·1A9 decreased significantly after 7 days. Hypoxic conditions affect the expression levels of UGT enzymes, thus the adjustment of dosage and interval should be considered in drug therapy that metabolized by UGT.
Collapse
|
25
|
Yada H, Ijiri Y, Uemura H, Tomioka Y, Okamoto H. Enhancement of Photoinduced Charge-Order Melting via Anisotropy Control by Double-Pulse Excitation in Perovskite Manganites: Pr_{0.6}Ca_{0.4}MnO_{3}. Phys Rev Lett 2016; 116:076402. [PMID: 26943548 DOI: 10.1103/physrevlett.116.076402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Indexed: 06/05/2023]
Abstract
To control the efficiency of photoinduced charge-order melting in perovskite manganites, we performed femtosecond pump-probe spectroscopy using double-pulse excitation on Pr_{0.6}Ca_{0.4}MnO_{3}. The results revealed that the transfer of the spectral weight from the near-infrared to infrared region by the second pump pulse is considerably enhanced by the first pump pulse and that the suppression of crystal anisotropy, that is, the decrease of long-range lattice deformations due to the charge order by the first pump pulse is a key factor to enhance the charge-order melting. This double-pulse excitation method can be applied to various photoinduced transitions in complex materials with electronic and structural instabilities.
Collapse
Affiliation(s)
- H Yada
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - Y Ijiri
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - H Uemura
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - Y Tomioka
- National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8561, Japan
| | - H Okamoto
- Department of Advanced Materials Science, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| |
Collapse
|
26
|
Kato R, Nishioka S, Nomura A, Ijiri Y, Miyamura M, Ukimura A, Okada Y, Kitaura Y, Hayashi T. Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia. Eur J Pharmacol 2015; 765:7-14. [PMID: 26276396 DOI: 10.1016/j.ejphar.2015.08.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 07/03/2015] [Accepted: 08/10/2015] [Indexed: 01/03/2023]
Abstract
Ezetimibe is as an inhibitor of NPC1L1 protein, which has a key role in cholesterol absorption. The aim of this study was to evaluate the influence of ezetimibe on the plasma lipid profile, atherosclerotic lesions, and cardiomyocyte ultrastructure in an animal model of atherosclerosis with intermittent hypoxia. Apolipoprotein E-knockout mice received a high-fat diet for 30 days. Then animals were exposed to intermittent hypoxia for 10 days or were maintained under normoxic conditions. In the ezetimibe group, ezetimibe (5 mg/kg/day) was added to the diet. Under normoxic conditions, the total cholesterol level was significantly lower in the ezetimibe group (63.6±6.6 mg/dl) than in the control group (116.3±16.9 mg/dl, P<0.001). Intermittent hypoxia accelerated atherosclerosis associated with increased superoxide production, which also caused degeneration of cardiomyocytes, mitochondrial abnormalities, and interstitial fibrosis. Compared with the control group, the ezetimibe group showed significantly less advanced atherosclerotic lesions and lower superoxide production in the thoracic aorta, as well as reduced oxidative stress, preservation of cardiomyocyte ultrastructure, and reduced interstitial fibrosis in the left ventricular myocardium. In conclusion, ezetimibe not only reduces total cholesterol, but also prevents the development of atherosclerosis and cardiovascular events due to intermittent hypoxia at least partly through suppression of oxidative stress.
Collapse
Affiliation(s)
- Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Satoshi Nishioka
- Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Atsuo Nomura
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Masatoshi Miyamura
- Department of Internal Medicine III, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
| | - Akira Ukimura
- Department of Internal Medicine III, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
| | - Yoshikatsu Okada
- Department of Pathology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
| | - Yasushi Kitaura
- Department of Internal Medicine III, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
| | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.
| |
Collapse
|
27
|
Krycka KL, Borchers JA, Booth RA, Ijiri Y, Hasz K, Rhyne JJ, Majetich SA. Krycka et al. reply. Phys Rev Lett 2015; 114:149702. [PMID: 25910168 DOI: 10.1103/physrevlett.114.149702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Indexed: 06/04/2023]
Affiliation(s)
- K L Krycka
- 1NIST Center for Neutron Research, Gaithersburg, Maryland 20899, USA
| | - J A Borchers
- 1NIST Center for Neutron Research, Gaithersburg, Maryland 20899, USA
| | - R A Booth
- 2Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Ijiri
- 3Oberlin College, Oberlin, Ohio 44074, USA
| | - K Hasz
- 3Oberlin College, Oberlin, Ohio 44074, USA
| | - J J Rhyne
- 4U.S. Department of Energy, Washington, DC 20585, USA
| | - S A Majetich
- 2Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| |
Collapse
|
28
|
Ijiri Y, Kato R, Sasaki D, Amano F, Tanaka K, Hayashi T. The effect of capsaicin on circulating biomarkers, soluble tumor necrosis factor and soluble tumor necrosis factor-receptor-1 and -2 levels in vivo using lipopolysaccharide-treated mice. Toxicol Rep 2014; 1:1062-1067. [PMID: 28962318 PMCID: PMC5598489 DOI: 10.1016/j.toxrep.2014.10.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Revised: 10/03/2014] [Accepted: 10/07/2014] [Indexed: 11/16/2022] Open
Abstract
The circulating soluble tumor necrosis factor (sTNF) and sTNF-receptor (R) 1 and -R2 have known as septic biomarker. The pungent component of capsicum, capsaicin (Cap), has several associated physiological activities, including anti-oxidant, anti-bacterial and anti-inflammatory effects. The aim of this study was to elucidate the effect of Cap on circulating sTNF and sTNF-R1 and -R2 in vivo using lipopolysaccharide (LPS)-treated mice. LPS (20 mg/kg, ip)-treated group was significantly increased circulating sTNF, sTNF-R1, and -R2 and TNF-α mRNA expression levels compared to the vehicle group. Treatment with LPS (20 mg/kg, ip) + Cap (4 mg/kg, sc)-treated group was significantly decreased both circulating sTNF levels (after 1 h only) and TNF-α mRNA expression (after 6 h) compared to the LPS-treated group. There is an early increase in circulating sTNF, sTNR-R1, and -R2 observed in the LPS-treated mice. Since Cap inhibits this initial increase as biomarkers, circulating sTNF, it is considered a potent treatment option for TNF-α-related diseases, such as septicemia. In conclusion, Cap interferes with TNF-α mRNA transcription and exerts an inhibiting effect on TNF-α release from macrophages in the early phase after LPS stimulation. Thus, Cap is considered a potent agent for the treatment of TNF-α-related diseases, such as septicemia.
Collapse
Affiliation(s)
- Yoshio Ijiri
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Ryuji Kato
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Daisuke Sasaki
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Fumio Amano
- Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Kazuhiko Tanaka
- Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyosi-ku, Osaka 546-0002, Japan
| | - Tetsuya Hayashi
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| |
Collapse
|
29
|
Kato R, Nomura A, Sakamoto A, Yasuda Y, Amatani K, Nagai S, Sen Y, Ijiri Y, Okada Y, Yamaguchi T, Izumi Y, Yoshiyama M, Tanaka K, Hayashi T. Hydrogen gas attenuates embryonic gene expression and prevents left ventricular remodeling induced by intermittent hypoxia in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 2014; 307:H1626-33. [PMID: 25281567 DOI: 10.1152/ajpheart.00228.2014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The prevalence of sleep apnea is very high in patients with heart failure (HF). The aims of this study were to investigate the influence of intermittent hypoxia (IH) on the failing heart and to evaluate the antioxidant effect of hydrogen gas. Normal male Syrian hamsters (n = 22) and cardiomyopathic (CM) hamsters (n = 33) were exposed to IH (repeated cycles of 1.5 min of 5% oxygen and 5 min of 21% oxygen for 8 h during the daytime) or normoxia for 14 days. Hydrogen gas (3.05 vol/100 vol) was inhaled by some CM hamsters during hypoxia. IH increased the ratio of early diastolic mitral inflow velocity to mitral annulus velocity (E/e', 21.8 vs. 16.9) but did not affect the LV ejection fraction (EF) in normal Syrian hamsters. However, IH increased E/e' (29.4 vs. 21.5) and significantly decreased the EF (37.2 vs. 47.2%) in CM hamsters. IH also increased the cardiomyocyte cross-sectional area (672 vs. 443 μm(2)) and interstitial fibrosis (29.9 vs. 9.6%), along with elevation of oxidative stress and superoxide production in the left ventricular (LV) myocardium. Furthermore, IH significantly increased the expression of brain natriuretic peptide, β-myosin heavy chain, c-fos, and c-jun mRNA in CM hamsters. Hydrogen gas inhalation significantly decreased both oxidative stress and embryonic gene expression, thus preserving cardiac function in CM hamsters. In conclusion, IH accelerated LV remodeling in CM hamsters, at least partly by increasing oxidative stress in the failing heart. These findings might explain the poor prognosis of patients with HF and sleep apnea.
Collapse
Affiliation(s)
- Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Atsuo Nomura
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Aiji Sakamoto
- Laboratory of Vascular Biology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Yuki Yasuda
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Koyuha Amatani
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Sayuri Nagai
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Yoko Sen
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Yoshikatsu Okada
- Department of Pathology, Osaka Medical College, Daigakumachi, Takatsuki, Japan
| | - Takehiro Yamaguchi
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan; and
| | - Yasukatsu Izumi
- Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Minoru Yoshiyama
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan; and
| | - Kazuhiko Tanaka
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan;
| |
Collapse
|
30
|
Krycka KL, Borchers JA, Booth RA, Ijiri Y, Hasz K, Rhyne JJ, Majetich SA. Origin of surface canting within Fe3O4 nanoparticles. Phys Rev Lett 2014; 113:147203. [PMID: 25325655 DOI: 10.1103/physrevlett.113.147203] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Indexed: 05/27/2023]
Abstract
The nature of near-surface spin canting within Fe3O4 nanoparticles is highly debated. Here we develop a neutron scattering asymmetry analysis which quantifies the canting angle to between 23° and 42° at 1.2 T. Simultaneously, an energy-balance model is presented which reproduces the experimentally observed evolution of shell thickness and canting angle between 10 and 300 K. The model is based on the concept of Td site reorientation and indicates that surface canting involves competition between magnetocrystalline, dipolar, exchange, and Zeeman energies.
Collapse
Affiliation(s)
- K L Krycka
- NIST Center for Neutron Research, Gaithersburg, Maryland 20899, USA
| | - J A Borchers
- NIST Center for Neutron Research, Gaithersburg, Maryland 20899, USA
| | - R A Booth
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Ijiri
- Oberlin College, Oberlin, Ohio 44074, USA
| | - K Hasz
- Oberlin College, Oberlin, Ohio 44074, USA
| | - J J Rhyne
- U.S. Department of Energy, Washington, D.C. 20585, USA
| | - S A Majetich
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| |
Collapse
|
31
|
Sasaki M, Nakagawa T, Nomura A, Kato R, Ijiri Y, Yamaguchi T, Izumi Y, Yoshiyama M, Asahi M, Hayashi T. Role of O-Linked N-Acetyl Glucosamine Posttranslational Modification in Intermittent Hypoxia-induced Cardiac Remodeling. J Card Fail 2014. [DOI: 10.1016/j.cardfail.2014.07.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Muroya M, Nomura A, Kato R, Ijiri Y, Sakamoto A, Yamaguchi T, Izumi Y, Yoshiyama M, Tanaka K, Hayashi T. Intermittent Hypoxia Relevant to Sleep Apnea Increases Oxidative Stress and Accelerates Cardiac Remodeling in Cardiomyopathic Hamster. J Card Fail 2014. [DOI: 10.1016/j.cardfail.2014.07.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Hayashi T, Sasaki M, Watanabe A, Furukawa Y, Nomura A, Uehashi W, Kato R, Ijiri Y, Nakagawa T, Asahi M, Yamaguchi T, Izumi Y, Yoshiyama M. O-LINKED N-ACETYL GLUCOSAMINE (O-GLCNAC) REGULATES AUTOPHAGY AND APOPTOSIS IN CARDIOMYOCYTES: A DOUBLE-EDGED SWORD IN INTERMITTENT HYPOXIA-INDUCED CARDIAC REMODELING. J Am Coll Cardiol 2014. [DOI: 10.1016/s0735-1097(14)60868-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
34
|
Ijiri Y, Kato R, Sadamatsu M, Takano M, Okada Y, Tanaka K, Hayashi T. Chronological changes in circulating levels of soluble tumor necrosis factor receptors 1 and 2 in rats with carbon tetrachloride-induced liver injury. Toxicology 2014; 316:55-60. [PMID: 24389507 DOI: 10.1016/j.tox.2013.12.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 12/06/2013] [Accepted: 12/22/2013] [Indexed: 11/19/2022]
Abstract
Carbon tetrachloride (CCl₄) facilitates the generation of hepatotoxins that can result in morphologic abnormalities, and these abnormalities are reasonably characteristic and reproducible for each particular toxin. It is also known that tumor necrosis factor-alpha (TNF-α) may participate in CCl₄-induced liver injury (CILI). In this study, we observed the chronological changes in circulating soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and -R2) in rats with CILI. Laboratory data; circulating levels of TNF-α, sTNF-R1, and sTNF-R2; and TNF-α levels in liver tissues were measured at various time-points. In the CCl₄ group, the plasma aspartate aminotransferase (AST, 7694±3041IU/l)/alanine aminotransferase (ALT, 3241±2159 IU/l) levels peaked at 48 h after CCl₄ administration, but the other laboratory data did not differ significantly from the corresponding data in the controls. Centrilobular hepatocyte necrosis and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells near the central vein area were observed via hematoxylin eosin (HE) and TUNEL staining, respectively, at 24 and 48 h after CCl₄ administration. Compared to the control group, the CCl₄ group did not show significantly the increased circulating TNF-α levels. But TNF-α levels in the liver tissues first peaked at 1h (5261±2253 pg/g liver), and a second peak was observed at 12h (3806±533 pg/g liver) after CCl₄ administration. Compared to the control group, the CCl₄ group showed significantly increased circulating levels of both sTNF-R1 (797±121pg/ml) and sTNF-R2 (5696±626 pg/ml) 1h after CCl₄ administration. Since the hepatocyte apoptosis may be resulted from binding of TNF-α with TNF-R1 at 24h after administration, and consequently the circulating TNF-R2 level might be approximately 10-fold higher than the circulating TNF-R1 level. In conclusion, increased circulating levels of sTNF-R1 and -R2 potentially contribute to drug-induced liver injury, together with AST/ALT.
Collapse
Affiliation(s)
- Yoshio Ijiri
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.
| | - Ryuji Kato
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Maiko Sadamatsu
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Mina Takano
- Pharmacotherapy II, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Yoshikatsu Okada
- Department of Pathology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
| | - Kazuhiko Tanaka
- Kidney Center, Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyoshi-ku, Osaka 546-0002, Japan
| | - Tetsuya Hayashi
- Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| |
Collapse
|
35
|
Kato R, Shigemoto K, Akiyama H, Ieda A, Ijiri Y, Hayashi T. Human Hepatocarcinoma Functional Liver Cell-4 Cell Line Exhibits High Expression of Drug-Metabolizing Enzymes in Three-Dimensional Culture. Biol Pharm Bull 2014; 37:1782-7. [DOI: 10.1248/bpb.b14-00438] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Kota Shigemoto
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Hiromasa Akiyama
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Asaka Ieda
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
36
|
Fujiwara Y, Nomura A, Kato R, Miyamura M, Ijiri Y, Ishizaka N, Hayashi T. Azilsartan Reduces Oxidative Stress and Attenuates Cardiac Remodeling Induced by Hypoxia in Rats. J Card Fail 2013. [DOI: 10.1016/j.cardfail.2013.08.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Ijiri Y, Poudel C, Williams P, Moore L, Orita T, Zborowski M. Inverted Linear Halbach Array for Separation of Magnetic Nanoparticles. IEEE Trans Magn 2013; 49:3449-3452. [PMID: 25382864 PMCID: PMC4224115 DOI: 10.1109/tmag.2013.2244577] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A linear array of Nd-Fe-B magnets has been designed and constructed in an inverted Halbach configuration for use in separating magnetic nanoparticles. The array provides a large region of relatively low magnetic field, yet high magnetic field gradient in agreement with finite element modeling calculations. The magnet assembly has been combined with a flow channel for magnetic nanoparticle suspensions, such that for an appropriate distance away from the assembly, nanoparticles of higher moment aggregate and accumulate against the channel wall, with lower moment nanoparticles flowing unaffected. The device is demonstrated for iron oxide nanoparticles with diameters of ~ 5 and 20 nm. In comparison to other approaches, the inverted Halbach array is more amenable to modeling and to scaling up to preparative quantities of particles.
Collapse
Affiliation(s)
- Y. Ijiri
- Department of Physics and Astronomy, Oberlin College, Oberlin, OH 44074 USA
| | - C. Poudel
- Department of Physics and Astronomy, Oberlin College, Oberlin, OH 44074 USA
| | - P.S. Williams
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA
- Cambrian Technologies, Inc., Cleveland, OH 44109 USA
| | - L.R. Moore
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA
| | - T. Orita
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA
| | - M. Zborowski
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA
| |
Collapse
|
38
|
Hirano M, Ogita-Nakanishi H, Miyachi W, Hannya N, Yamamoto-Kimoto Y, Sakurai K, Miyoshi-Higashino M, Tashiro-Yamaji J, Kato R, Ijiri Y, Tanaka K, Kanazawa A, Terada T, Kawata R, Takenaka H, Kubota T, Yoshida R. Essential role of macrophages in the initiation of allergic rhinitis in mice sensitized intranasally once with cedar pollen: regulation of class switching of immunoglobulin in B cells by controlling interleukin-4 production in T cells of submandibular lymph nodes. Microbiol Immunol 2012; 56:392-405. [PMID: 22404751 DOI: 10.1111/j.1348-0421.2012.00449.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The production of allergen-specific IgE antibodies (Abs) in allergen-sensitized patients or animals has a mutual relationship with the immunologic response leading to allergic rhinitis. We recently reported that, after an intranasal injection of cedar pollen into mice, an interleukin-4 (IL-4)-dependent increase in serum nonspecific IgE Abs was a prerequisite for the production of serum allergen-specific IgE Abs. Here, we explored which lymphoid organs were responsive to the intranasally injected allergen and how IL-4 and IgE Abs were produced in the lymphocytes. Time-dependent changes in the total cell numbers and in in vitro IgE Ab production in various lymphoid organs revealed that the submandibular lymph nodes were the main responsible organ. After treatment with allergen (for IgE production) or allergen and complete Freund's adjuvant (for IgG production), we separated submandibular lymph node cells into macrophage-, lymphocyte-, and granulocyte-rich populations by discontinuous Percoll density-gradient centrifugation. Unexpectedly, bulk cells, but not the lymphocyte- or macrophage-rich populations, produced significant amounts of IL-4, IgE, and IgG; whereas production was restored by addition of Mac-1(+) cells from the macrophage-rich to the lymphocyte-rich fraction. Furthermore, a combination of the lymphocyte-rich population (for IgG [or IgE]) production) and the macrophage-rich population (for IgE [or IgG]) production) produced a large amount of IgE (or IgG). These results indicate that, in the initiation of allergic rhinitis, macrophages in the submandibular lymph nodes are essential not only for IL-4 or immunoglobulin production, but also for class switching of immunoglobulin in lymphocytes.
Collapse
Affiliation(s)
- Masayo Hirano
- Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hirotani Y, Doi A, Ikeda K, Kato R, Ijiri Y, Tanaka K, Myotoku M. Effects of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on hyperinsulinemia induced in rats fed a sucrose-rich diet. Drug Discov Ther 2012; 5:181-4. [PMID: 22466298 DOI: 10.5582/ddt.2011.v5.4.181] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We investigated the effects of a Chinese herbal medicine, Gosha-jinki-gan (GJG), on the regulation of insulin levels in rats fed a sucrose-rich diet (SRD). Normal Wistar rats in the SRD group were fed an SRD for 4 weeks. Increased dietary sucrose did not alter plasma glucose levels but it increased plasma insulin levels at 2 and 4 weeks in the SRD-fed rats relative to control rats that were fed standard chow. GJG treatment significantly suppressed the SRD-induced elevation in plasma insulin levels. These results suggest that GJG improves hyperinsulinemia caused by an SRD.
Collapse
Affiliation(s)
- Y Hirotani
- Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohatani University, Osaka, Japan
| | | | | | | | | | | | | |
Collapse
|
40
|
Arai M, Ogita-Nakanishi H, Lee K, Yoshimura K, Kawata R, Kanazawa A, Terada T, Takenaka H, Sato T, Endo Y, Kato R, Ijiri Y, Tanaka K, Tashiro-Yamaji J, Kubota T, Yoshida R. Role of cytokines in lavage or drainage fluid after hemithyroidectomy in wound healing: involvement of histamine in the acceleration and delay of wound healing. Wound Repair Regen 2012; 20:158-65. [PMID: 22380688 DOI: 10.1111/j.1524-475x.2012.00770.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Wound healing is a sophisticated biologic process. In the case of hemithyroidectomy, the operation time is relatively short with small tissue damage and without skin excision, and bacterial contamination before, during, and after the operation is uncommon. Here, we explored which cytokine(s) affected the rates of healing of skin wounds after hemithyroidectomy of 29 patients. We assessed the amounts of cytokines (e.g., interleukin-6, platelet-derived growth factor, basic fibroblast growth factor, vascular endothelial growth factor, and tumor necrosis factor-α) in either the preoperative or postoperative lavage fluids, or in the drainage fluids on postoperative days (PODs) 1-8. All of these cytokines showed a similar pattern; after reaching a peak on POD1, the production fell sharply on POD2-8, revealing that wound healing commenced on POD1. The rates of wound healing were inversely related to the levels of histamine in six patients (i.e., those with the three largest and those with the three smallest total volumes of drainage fluid on POD1): high (or low) levels of histamine in the postoperative lavage fluids with low (or high) levels in the drainage fluids on POD1 caused earlier (or the delay of) wound healing, suggesting involvement of histamine in the acceleration and delay of wound healing.
Collapse
Affiliation(s)
- Miku Arai
- Department of Physiology, Osaka Medical College, Takatsuki, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kobayashi T, Hirose J, Sano K, Kato R, Ijiri Y, Takiuchi H, Tanaka K, Goto E, Tamai H, Nakano T. Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicol Environ Saf 2012; 78:123-127. [PMID: 22154144 DOI: 10.1016/j.ecoenv.2011.11.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Revised: 10/31/2011] [Accepted: 11/16/2011] [Indexed: 05/31/2023]
Abstract
Antineoplastics in excreta from patients have been considered to be one of the origins of cytotoxic, carcinogenic, teratogenic, and mutagenic contaminants in surface water. Recent studies have demonstrated that antineoplastics in clinical wastewater can be detoxified by electrolysis. In this study, to develop a method for the detoxification of antineoplastics in excreta, methotrexate solution in the presence of human urine was electrolyzed and evaluated. We found that urine inhibits detoxification by electrolysis; however, this inhibition decreased by diluting urine. In urine samples, the concentrations of active chlorine generated by anodic oxidation from 0.9% NaCl solution for inactivation of antineoplastics increased in dilution-dependent and time-dependent manner. These results indicate that electrolysis with platinum-based iridium oxide composite electrode is a possible method for the detoxification of a certain antineoplastic in urine.
Collapse
Affiliation(s)
- Toyohide Kobayashi
- Project Team for Medical Application of Electrolysis, Central Research Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kato R, Higashitani A, Irie T, Kusukawa Y, Yamamoto Y, Nakagawa M, Urashima Y, Nagata M, Hayashi T, Ijiri Y, Tanaka K. Influence of capsaicin on fluctuation of digoxin pharmacokinetics in lipopolysaccharide-treated rats. Xenobiotica 2012; 42:798-807. [DOI: 10.3109/00498254.2012.663514] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
43
|
Abstract
This paper examines a stochastic process for Bose-Einstein statistics that is based on Gibrat's Law (roughly: the probability of a new occurrence of an event is proportional to the number of times it has occurred previously). From the necessary conditions for the steady state of the process are derived, under two slightly different sets of boundary conditions, the geometric distribution and the Yule distribution, respectively. The latter derivation provides a simpler method than the one earlier proposed by Hill [J. Amer. Statist. Ass. (1974) 69, 1017-1026] for obtaining the Pareto Law (a limiting case of the Yule distribution) from Bose-Einstein statistics. The stochastic process is applied to the phenomena of city sizes and growth.
Collapse
Affiliation(s)
- Y Ijiri
- Carnegie-Mellon University, Pittsburgh, Pennsylvania 15213
| | | |
Collapse
|
44
|
Kato R, Moriguchi J, Irie T, Nakagawa M, Kusukawa Y, Matsumura H, Ijiri Y, Tanaka K. Effects of lipopolysaccharide on P-glycoprotein expression and activity in the liver and kidneys. Eur J Pharmacol 2010; 636:155-8. [DOI: 10.1016/j.ejphar.2010.03.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Revised: 02/25/2010] [Accepted: 03/12/2010] [Indexed: 10/19/2022]
|
45
|
Krycka KL, Booth RA, Hogg CR, Ijiri Y, Borchers JA, Chen WC, Watson SM, Laver M, Gentile TR, Dedon LR, Harris S, Rhyne JJ, Majetich SA. Core-shell magnetic morphology of structurally uniform magnetite nanoparticles. Phys Rev Lett 2010; 104:207203. [PMID: 20867056 DOI: 10.1103/physrevlett.104.207203] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Indexed: 05/15/2023]
Abstract
A new development in small-angle neutron scattering with polarization analysis allows us to directly extract the average spatial distributions of magnetic moments and their correlations with three-dimensional directional sensitivity in any magnetic field. Applied to a collection of spherical magnetite nanoparticles 9.0 nm in diameter, this enhanced method reveals uniformly canted, magnetically active shells in a nominally saturating field of 1.2 T. The shell thickness depends on temperature, and it disappears altogether when the external field is removed, confirming that these canted nanoparticle shells are magnetic, rather than structural, in origin.
Collapse
Affiliation(s)
- K L Krycka
- NIST Center for Neutron Research, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kato R, Yamashita S, Moriguchi J, Nakagawa M, Tsukura Y, Uchida K, Amano F, Hirotani Y, Ijiri Y, Tanaka K. Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2. Innate Immun 2008; 14:291-7. [DOI: 10.1177/1753425908095956] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
It has been reported that infection interferes with drug metabolism, resulting in changes in pharmacokinetics. In this study, we investigated the effects of lipopolysaccharide (LPS) on hepatic total cytochrome P450 (CYP), CYP3A2, and CYP2C11 contents in a transient, LPS-induced, endotoxemia model of rats. In addition, to assess the effects on CYP3A2 activities, the pharmacokinetics of midazolam (CYP3A2 substrate) and 1-OH-midazolam (metabolite of midazolam) were investigated. Hepatic total CYP contents were significantly low until day 3 ( P < 0.05) but returned to the control level on day 5. Hepatic CYP3A2 contents were significantly decreased on day 1 until day 5 ( P < 0.05) but returned to the control level on day 7. Hepatic CYP2C11 contents were continuously low until day 7, and lowest on day 3. The AUC of 1-OH-midazolam was significantly decreased on day 1 after LPS administration ( P < 0.01). In conclusion, LPS (5 mg/kg) challenge decreased hepatic total CYP, CYP3A2, and CYP2C11 contents and also decreased the activities of hepatic CYP3A2. It took at least 7 days for hepatic total CYP and CYP3A2 to recover to control levels, and it was suggested that the changes of hepatic total CYP contents might correlate with those of hepatic CYP3A2 contents and activities. Additionally, it is shown that their changes might reflect the recovery process from inflammation.
Collapse
Affiliation(s)
- Ryuji Kato
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Satoshi Yamashita
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Jun Moriguchi
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Machiko Nakagawa
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Yuri Tsukura
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | | | - Fumio Amano
- Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Yoshihiko Hirotani
- Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka-Ohtani University, Tondabayashi, Japan
| | - Yoshio Ijiri
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan
| | - Kazuhiko Tanaka
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan,
| |
Collapse
|
47
|
Kobayashi T, Hirose J, Sano K, Hiro N, Ijiri Y, Takiuchi H, Tamai H, Takenaka H, Tanaka K, Nakano T. Evaluation of an electrolysis apparatus for inactivating antineoplastics in clinical wastewater. Chemosphere 2008; 72:659-665. [PMID: 18423519 DOI: 10.1016/j.chemosphere.2008.02.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2007] [Revised: 02/13/2008] [Accepted: 02/13/2008] [Indexed: 05/26/2023]
Abstract
We recently reported a system for inactivating antineoplastics in which sodium hypochlorite is supplied by the electrolysis of sodium chloride solution. In this study, we designed an electrolysis apparatus for inactivating the cytotoxicity of antineoplastics in clinical wastewater using the system. The apparatus consists of an electrolysis cell with platinum-iridium electrodes, a pool tank, a circulating system for wastewater, a safety system for explosive gas and overflow, and an exhaust duct. The free chlorine concentration increased linearly up to 6500 mg l(-1), and pH also increased to 9.0-10.0 within 2h, when 0.9% sodium chloride solution was electrolyzed. We examined its efficacy with model and clinical wastewaters. The reciprocal of dilution factor for disappearance of cytotoxicity using Molt-4 cells was compared before and after electrolysis. In the model wastewater, that was 9.10 x 10(4) before electrolysis, and 3.56 x 10(2) after 2h of electrolysis. In the clinical wastewater (n=26), that was 6.90 x 10(3)-1.02 x 10(6) before electrolysis, and 1.08 x 10(2)-1.45 x 10(4) after 2h of electrolysis. Poisonous and explosive gases released by the electrolysis were measured; however, they were found to be negligible in terms of safety. The environmental load was evaluated by carbon dioxide generation as an index and it was found that the carbon dioxide generated by the electrolysis method was 1/70 lower than that by the dilution method with tap water. Moreover, the cost of the electrolysis method was 1/170 lower than that of the dilution method. This method was found to be both effective and economically valuable.
Collapse
Affiliation(s)
- Toyohide Kobayashi
- Project Team for Medical Application of Electrolysis, Central Research Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kato R, Fujiwara A, Kawai T, Moriguchi J, Nakagawa M, Tsukura Y, Uchida K, Amano F, Hirotani Y, Ijiri Y, Tanaka K. Changes in Digoxin Pharmacokinetics Treated with Lipopolysaccharide in Wistar Rats. Biol Pharm Bull 2008; 31:1221-5. [DOI: 10.1248/bpb.31.1221] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryuji Kato
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Azusa Fujiwara
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Takako Kawai
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Jun Moriguchi
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Machiko Nakagawa
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Yuri Tsukura
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | | | - Fumio Amano
- Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences
| | - Yoshihiko Hirotani
- Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University
| | - Yoshio Ijiri
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Kazuhiko Tanaka
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
49
|
Kato R, Tokunaga Y, Kawai T, Tsukura Y, Amano F, Hirotani Y, Ijiri Y, Tanaka K. Effects of CpG-DNA from Escherichia coli on Digoxin Pharmacokinetics. Biol Pharm Bull 2008; 31:1226-9. [DOI: 10.1248/bpb.31.1226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryuji Kato
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Yuka Tokunaga
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Takako Kawai
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Yuri Tsukura
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Fumio Amano
- Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences
| | - Yoshihiko Hirotani
- Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University
| | - Yoshio Ijiri
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| | - Kazuhiko Tanaka
- Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
50
|
Tsukura Y, Mori M, Hirotani Y, Ikeda K, Amano F, Kato R, Ijiri Y, Tanaka K. Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells. Biol Pharm Bull 2007; 30:1982-6. [PMID: 17917278 DOI: 10.1248/bpb.30.1982] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Recent studies suggest that capsaicin (Cap), a major constituent of hot pepper, may affect the function and permeability of the intestinal mucosa in vitro. However, the relationships between the dose of Cap and the barrier and/or transporter functions on intestinal epithelial cells are unknown. The aim of this study was to investigate whether Cap initiates cellular injury and alter epithelial permeability in Caco-2 cells. Cellular toxicity, as measured using a lactate dehydrogenase release assay, was not observed at high concentrations of Cap (up to 300 microM). When cell viability was measured by a WST-1 assay (tetrazolium salt-based assay), damage to Caco-2 monolayers was observed at doses of 200 and 300 microM of Cap. The barrier function of tight junctions was assessed by measuring transepithelial electrical resistance (TEER) in Caco-2 cells. Treatment of Caco-2 cells with Cap at doses above 100 microM significantly decreased the TEER compared to treatment with buffer alone for 2 h (p<0.05). We next examined the effects of Cap on the activity of P-glycoprotein (P-gp) found on transcellular transporters. At doses of 100 and 200 microM, Cap inhibited the transport of rhodamine 123 by P-gp-mediated efflux in Caco-2 cells. Cap thus exhibited inhibitory effects on P-gp. The results of this study indicate that Cap, a dietary phytochemical, causes functional and structural changes in Caco-2 cell monolayers at noncytotoxic doses (less than 100 microM of Cap). The concomitant administration of Cap with drugs that are substrates of P-gp might increase the plasma concentrations of such drugs.
Collapse
Affiliation(s)
- Yuri Tsukura
- Laboratory of Clinical Pharmacy & Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | | | | | | | | | | | | | | |
Collapse
|